

Giulio Cavalli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1786351/giulio-cavalli-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

3,585
citations

30
h-index

59
g-index

132
ext. papers

4,763
ext. citations

5.9
avg, IF

5.94
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 112 | Successful use of cyclosporin A and interleukin-1 blockers combination in VEXAS syndrome: a single-centre case series.. <i>Arthritis and Rheumatology</i> , 2022 , | 9.5 | 1 |
| 111 | 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.. <i>Annals of the Rheumatic Diseases</i> , 2022 , | 2.4 | 5 |
| 110 | Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.. <i>RMD Open</i> , 2022 , 8, | 5.9 | 1 |
| 109 | Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.. <i>RMD Open</i> , 2022 , 8, | 5.9 | 3 |
| 108 | Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 2022 , | 2.2 | |
| 107 | Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. <i>RMD Open</i> , 2022 , 8, e002167 | 5.9 | 3 |
| 106 | Maladaptive autophagy in the pathogenesis of autoimmune epithelitis in Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2021 , | 9.5 | 3 |
| 105 | Myocarditis as a manifestation of Erdheim-Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy. <i>Scandinavian Journal of Rheumatology</i> , 2021 , 1-3 | 1.9 | 0 |
| 104 | The course of action for effective anti-cytokine treatment in COVID-19. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1353-1354 | 35.1 | 0 |
| 103 | The choice of early treatment and the impact of future relapses in adult onset Still's disease. <i>Rheumatology</i> , 2021 , 60, 2500-2501 | 3.9 | |
| 102 | The right place for IL-1 inhibition in COVID-19. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 223-224 | 35.1 | 21 |
| 101 | Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021 , 12, 653950 | 8.4 | 7 |
| 100 | Interleukin 1α comprehensive review on the role of IL-1 in the pathogenesis and treatment of autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2021 , 20, 102763 | 13.6 | 44 |
| 99 | Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. <i>European Journal of Internal Medicine</i> , 2021 , 86, 34-40 | 3.9 | 39 |
| 98 | Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , 2021 , 3, e253-e261 | 14.2 | 75 |
| 97 | The anti-inflammatory cytokine interleukin-37 is an inhibitor of trained immunity. <i>Cell Reports</i> , 2021 , 35, 108955 | 10.6 | 20 |
| 96 | POS1347 IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILL'S DISEASE PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 955.3-956 | 2.4 | |

| | | | |
|----|--|------|-----|
| 95 | POS0370 TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 415-415 | 2.4 | |
| 94 | Impact of rare and common genetic variation in the interleukin-1 pathway on human cytokine responses. <i>Genome Medicine</i> , 2021 , 13, 94 | 14.4 | 1 |
| 93 | POS1336 RETROPERITONEAL FIBROSIS IN ERDHEIM-CHESTER DISEASE HAS UNIQUE PRESENTING AND PROGNOSTIC FEATURES: A SINGLE CENTRE RETROSPECTIVE COMPARATIVE COHORT STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 950-951 | 2.4 | |
| 92 | POS1341 TOCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 953.1-953.4 | 2.4 | 0 |
| 91 | Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021 , 138, 1554-1569 | 2.2 | 2 |
| 90 | Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. <i>Nature Communications</i> , 2021 , 12, 4559 | 17.4 | 3 |
| 89 | Anakinra in COVID-19-How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarro-Millán et al. <i>Arthritis and Rheumatology</i> , 2021 , 73, 549 | 9.5 | |
| 88 | Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. <i>Microvascular Research</i> , 2021 , 133, 104071 | 3.7 | 21 |
| 87 | A Novel Histiocytosis With Synovial and Skin Involvement. <i>Annals of Internal Medicine</i> , 2021 , 174, 273-274 | 2.4 | 2 |
| 86 | Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1-6 | 5.3 | 6 |
| 85 | The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab015 | 1.1 | 0 |
| 84 | Canakinumab injection for the treatment of active Still's disease, including adult-onset Still's disease. <i>Expert Opinion on Orphan Drugs</i> , 2021 , 9, 77-86 | 1.1 | 0 |
| 83 | Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, e143-e146 | 1.1 | 10 |
| 82 | Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021 , 27, 1752-1760 | 50.5 | 93 |
| 81 | In the limelight: AA amyloidosis exposes TNF receptor-1 associated periodic syndrome. <i>Rheumatology</i> , 2021 , 60, 5493-5494 | 3.9 | |
| 80 | A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). <i>Frontiers in Medicine</i> , 2021 , 8, 723506 | 4.9 | 0 |
| 79 | Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology, The</i> , 2021 , 3, e690-e697 | 14.2 | 38 |
| 78 | Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e325-e331 | 14.2 | 612 |

| | | | |
|----|--|-----|-----|
| 77 | Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. <i>Frontiers in Medicine</i> , 2020 , 7, 42 | 4.9 | 6 |
| 76 | Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 536-544 | 2.4 | 25 |
| 75 | Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1277-1285 | 2.4 | 164 |
| 74 | Erdheim-Chester disease: An in vivo human model of M ϕ activation at the crossroad between chronic inflammation and cancer. <i>Journal of Leukocyte Biology</i> , 2020 , 108, 591-599 | 6.5 | 5 |
| 73 | Autophagy and Protein Secretion. <i>Journal of Molecular Biology</i> , 2020 , 432, 2525-2545 | 6.5 | 32 |
| 72 | Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 509-514 | 5.3 | 9 |
| 71 | FRI0506 EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILL'S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 851.1-852 | 2.4 | 33 |
| 70 | Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020 , 11, 598308 | 5.6 | 14 |
| 69 | FRI0484 SAFETY PROFILE, CLINICAL AND RADIOLOGICAL EFFICACY OF ANAKINRA, TARGETED AND COMBINED TREATMENT IN ERDHEIM-CHESTER DISEASE. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 839.1-840 | 2.4 | |
| 68 | SAT0519 DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1215-1216 | 2.4 | |
| 67 | Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020 , 76, 43-49 | 3.9 | 270 |
| 66 | Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2020 , 47, 1780-1784 | 4.1 | 0 |
| 65 | Current treatment options and safety considerations when treating adult-onset Still's disease. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1549-1558 | 4.1 | 8 |
| 64 | Autophagy in the regulation of protein secretion in immune cells 2020 , 141-173 | | |
| 63 | Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. <i>European Journal of Internal Medicine</i> , 2020 , 82, 23-24 | 3.9 | |
| 62 | Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , 2020 , 59, 171-175 | 3.9 | 17 |
| 61 | Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2019 , 48, 482-490 | 1.9 | 12 |
| 60 | Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. <i>Frontiers in Pharmacology</i> , 2019 , 10, 296 | 5.6 | 17 |

| | | | |
|----|--|------|-------|
| 59 | Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease. <i>Arthritis Research and Therapy</i> , 2019 , 21, 54 | 5.7 | 25 |
| 58 | Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, e140-e141 | 1.1 | 1 |
| 57 | Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1313-1322 | 5.1 | 6 |
| 56 | Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2019 , | 2.4 | 9 |
| 55 | AB0621 GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS 2019 , | | 2 |
| 54 | Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use. <i>Journal of Clinical Rheumatology</i> , 2019 , | 1.1 | 4 |
| 53 | 3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 862-864 | 2.4 | 3 |
| 52 | Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. <i>International Journal of Cardiology</i> , 2018 , 252, 21-23 | 3.2 | 12 |
| 51 | Suppression of inflammation and acquired immunity by IL-37. <i>Immunological Reviews</i> , 2018 , 281, 179-190 | 1.3 | 140 |
| 50 | Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition. <i>Annals of Internal Medicine</i> , 2018 , 169, 819-820 | 8 | 26 |
| 49 | Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , 2018 , 57, e11-e12 | 3.9 | 24 |
| 48 | Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease. <i>Frontiers in Immunology</i> , 2018 , 9, 1233 | 8.4 | 32 |
| 47 | Myocarditis: An Interleukin-1-Mediated Disease?. <i>Frontiers in Immunology</i> , 2018 , 9, 1335 | 8.4 | 30 |
| 46 | Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. <i>Journal of Biological Chemistry</i> , 2018 , 293, 14224-14236 | 5.4 | 14236 |
| 45 | Letter by Campochiaro et al Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". <i>Circulation</i> , 2018 , 137, 2421-2422 | 16.7 | 2 |
| 44 | The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>Oncotarget</i> , 2018 , 7, e1440929 | 7.2 | 13 |
| 43 | Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it?. <i>European Review for Medical and Pharmacological Sciences</i> , 2018 , 22, 2189-2190 | 2.9 | 2 |
| 42 | Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. <i>Journal of Neurology</i> , 2018 , 265, 273-284 | 5.5 | 12 |

| | | | |
|----|---|------|-----|
| 41 | Publications Are Not the Finish Line: Focusing on Societal Rather Than Publication Impact. <i>Frontiers in Medicine</i> , 2018 , 5, 314 | 4.9 | 2 |
| 40 | Anakinra Therapy for Non-cancer Inflammatory Diseases. <i>Frontiers in Pharmacology</i> , 2018 , 9, 1157 | 5.6 | 137 |
| 39 | Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, 2313-2318 | 11.5 | 60 |
| 38 | Advances in potential targeted therapies for Erdheim-Chester disease. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 1-8 | 1.1 | 4 |
| 37 | QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk. <i>International Journal of Cardiology</i> , 2017 , 239, 33 | 3.2 | 15 |
| 36 | Tocilizumab in patients with multisystem Erdheim-Chester disease. <i>OncolImmunology</i> , 2017 , 6, e1318237 | 7.2 | 23 |
| 35 | Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. <i>Frontiers in Pharmacology</i> , 2017 , 8, 369 | 5.6 | 68 |
| 34 | Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure. <i>Frontiers in Immunology</i> , 2017 , 8, 131 | 8.4 | 42 |
| 33 | Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. <i>Rheumatology</i> , 2016 , 55, 2220-2229 | 3.9 | 56 |
| 32 | Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>OncolImmunology</i> , 2016 , 5, e1181244 | 7.2 | 10 |
| 31 | MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1363-8 | 11.5 | 65 |
| 30 | Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1357-62 | 11.5 | 33 |
| 29 | Methotrexate in refractory bilateral juvenile temporal arteritis: Report of a case. <i>Modern Rheumatology</i> , 2016 , 26, 276-7 | 3.3 | 4 |
| 28 | Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera: A Case Report. <i>Medicine (United States)</i> , 2016 , 95, e3697 | 1.8 | 6 |
| 27 | Treating Life-Threatening Myocarditis by Blocking Interleukin-1. <i>Critical Care Medicine</i> , 2016 , 44, e751-4 | 1.4 | 51 |
| 26 | Hypertrophic cardiomyopathy secondary to hepatitis C virus-related vasculitis. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 2, e156-e157 | 1.9 | 2 |
| 25 | FRI0001 Treating Experimental Arthritis with The Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 426.1-426 | 2.4 | |
| 24 | Treating pulmonary silicosis by blocking interleukin 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 596-8 | 10.2 | 34 |

| | | | |
|----|---|------|-----|
| 23 | Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 45, 48-54 | 5.3 | 55 |
| 22 | Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. <i>Rheumatology</i> , 2015 , 54, 2134-44 | 3.9 | 76 |
| 21 | Erdheim-Chester disease. <i>European Journal of Internal Medicine</i> , 2015 , 26, 223-9 | 3.9 | 99 |
| 20 | Orthopnea with platydeoxia secondary to prominent Eustachian valve. <i>Intensive Care Medicine</i> , 2015 , 41, 918-9 | 14.5 | 2 |
| 19 | Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. <i>Autoimmunity Reviews</i> , 2015 , 14, 352-7 | 13.6 | 35 |
| 18 | BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1596-602 | 2.4 | 75 |
| 17 | An enlightening scan. <i>European Journal of Internal Medicine</i> , 2015 , 26, 68-9 | 3.9 | 1 |
| 16 | Efficacy and safety of biological agents in adult-onset Still's disease. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 309-14 | 1.9 | 51 |
| 15 | Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. <i>Blood</i> , 2014 , 124, 483-92 | 2.2 | 371 |
| 14 | THU0372 The Role of Echocardiography and Cardiac MRI in Erdheim-Chester Disease. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 311.1-311 | 2.4 | |
| 13 | Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease. <i>Frontiers in Immunology</i> , 2014 , 5, 281 | 8.4 | 35 |
| 12 | Aortic thrombosis secondary to clopidogrel-related thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2014 , 166, 470 | 4.5 | 0 |
| 11 | A bitter effect: thrombocytopenia induced by a quinidine-containing beverage. <i>American Journal of Medicine</i> , 2014 , 127, e1-2 | 2.4 | 2 |
| 10 | Charcot's arthropathy of the spine. <i>Arthritis and Rheumatism</i> , 2013 , 65, 342 | | 2 |
| 9 | The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1691-5 | 2.4 | 129 |
| 8 | Diagnosing Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, e19 | 2.4 | 9 |
| 7 | Charcot's arthropathy of the hip. <i>Journal of Rheumatology</i> , 2013 , 40, 1770 | 4.1 | 1 |
| 6 | AB0742 Pure peripheral giant cell arteritis: A systematic literature review of a poorly characterized clinical entity. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 681.2-681 | 2.4 | |

- 5 AB0746 Juvenile temporal arteritis: Report of a case and review of the literature. *Annals of the Rheumatic Diseases*, **2013**, 71, 681.6-681 2.4
- 4 THU0386 Efficacy of long-term treatment with biologic agents in refractory adult onset stilling disease: A single centre experience on 16 patients. *Annals of the Rheumatic Diseases*, **2013**, 71, 286.1-286^{2.4}
- 3 FRI0486 Cardiac cine mri in erdheim-chester disease: data from a large italian cohort. *Annals of the Rheumatic Diseases*, **2013**, 72, A539.2-A539 2.4
- 2 THU0209 Efficacy of anti-TNF therapy in 15 patients with refractory takayasu's arteritis: Long term unicentric follow-up. *Annals of the Rheumatic Diseases*, **2013**, 71, 226.1-226 2.4 4
- 1 THU0373 Clinical presentation of erdheim-chester disease: Data from a cohort of 10 patients and review of the literature. *Annals of the Rheumatic Diseases*, **2013**, 71, 281.3-282 2.4